Interventional Cardiology Devices Market Size, Share, Growth and Demand by Region and Forecast to 2031

-

 

Interventional Cardiology Devices Market Overview:

The global interventional cardiology devices market, valued at approximately $6.7 billion, is expected to grow at a CAGR of 2–3% through 2031. Key factors driving this growth include the expanding geriatric population and the associated rise in coronary artery disease, increasing prevalence of diabetes and the resulting higher risk of coronary heart disease, continuous technological advancements in interventional cardiology devices, and favorable reimbursement policies for interventional procedures.

Download Sample Copy: https://meditechinsights.com/interventional-cardiology-devices-market/request-sample/

Interventional cardiology is a specialized branch of cardiology that focuses on minimally invasive, catheter-based treatments for structural heart diseases. The field utilizes a wide range of devices such as catheters and sheaths, guidewires, balloons, stents, vascular closure devices, atherectomy devices, intravascular ultrasound (IVUS) systems, and other advanced tools. These devices are used to treat narrowed arteries, weakened or damaged blood vessels, heart valve disorders, and congenital heart defects.

APAC Interventional Cardiology Devices Market Expected to Record the Fastest Growth

The Asia-Pacific (APAC) region is projected to witness the highest growth in the interventional cardiology devices market over the next five years. Factors such as the rising prevalence of cardiovascular diseases and hypertension, significant unmet clinical needs, and increasing disposable incomes are creating substantial market opportunities across the region. China and India are expected to be the primary growth engines.

Recognizing the strong growth potential in APAC, leading market players are actively expanding their regional presence. For example, in March 2022, Boston Scientific established its second R&D center in India. This facility supports innovation across multiple therapy areas, including interventional cardiology, peripheral interventions, cardiac rhythm management, endoscopy, neuromodulation, urology, and pelvic health, while addressing patient needs across India, APAC, and globally.

Similarly, Abbott is strengthening its cardiovascular training and education infrastructure in China. The company operates two training centers: the Abbott Medical Advanced Technology Center in Beijing, which provides advanced cardiology education and hands-on experience, and the Crossroads-Abbott Academic Center in Shanghai, which offers interventional treatment training to physicians from across the country. These initiatives aim to improve access to standardized cardiovascular care, particularly in remote regions.

“China is one of the most prominent markets for cardiovascular diseases. The demand from patients for treatment and from physicians for training is enormous. This is why interventional cardiology device manufacturers are heavily investing in China.”
— Director, Leading Stent Manufacturer, United States

Download Sample Copy: https://meditechinsights.com/interventional-cardiology-devices-market/request-sample/

Technological Advancements Driving Market Growth

The interventional cardiology devices market is highly technology-driven and characterized by continuous product innovation. Notable developments include:

  • In May 2022, Medtronic received U.S. FDA approval for the Onyx Frontier™ drug-eluting stent (DES) for treating coronary artery disease. The device features an advanced delivery system and builds on the clinical performance of the Resolute Onyx™ DES.
  • In April 2022, Translumina launched VIVO ISAR, a next-generation dual-drug, polymer-free coated stent, across multiple international markets, including Europe. This technology combines sirolimus with probucol, enabling controlled drug release without the use of polymers, while maintaining strong safety and efficacy.
  • In March 2022, SIS Medical AG received FDA 510(k) clearance for its OPN NC® TWIN-Wall Super High Pressure PTCA Balloon. The device features a unique double-balloon technology, delivering high burst pressure (up to 35 atm) with low compliance, making it suitable for complex lesion preparation and post-dilatation of under-expanded stents.

Strategic Growth Initiatives by Market Players

The interventional cardiology devices market comprises both established players and emerging companies. Market participants are pursuing a mix of organic and inorganic growth strategies, including product launches and acquisitions, to strengthen their market position.

  • In April 2022, Transit Scientific received FDA clearance to expand the coronary use indication of its XO Cross® Support Catheter Platform, designed to support guidewire access, facilitate wire exchanges, and enable contrast or saline delivery.
  • In the same month, Boston Scientific completed its acquisition of Baylis Medical Company Inc., a provider of advanced transseptal access solutions and catheter-based support devices. This acquisition enhances Boston Scientific’s electrophysiology and structural heart portfolio, reinforcing its leadership in the cardiology space.

Browse Report: https://meditechinsights.com/interventional-cardiology-devices-market/

Market Outlook and Competitive Landscape

The interventional cardiology devices market is expected to maintain steady growth in the coming years, driven by the increasing burden of cardiovascular diseases, expanding opportunities in the APAC region, continuous technological innovation, and supportive reimbursement frameworks in major markets.

Key players operating in the global interventional cardiology devices market include Medtronic, Boston Scientific, Abbott, Medinol, Biotronik, SMT, Terumo, Lepu Medical, MicroPort, and others.

technologies, supporting the development of next-generation drug discovery assays.

Related Report:

HPV Testing and PAP Test Market - https://www.pharmiweb.com/press-release/2025-12-18/hpv-testing-and-pap-test-market-share-size-growth-forecast-till-2030

Cellular Health Screening Market - https://www.pharmiweb.com/press-release/2025-12-18/cellular-health-screening-market-2030-analysis-size-share-growth-trends-and-forecast

Hematology Market - https://www.pharmiweb.com/press-release/2025-12-18/hematology-market-outlook-2030-industry-trends-and-competitive-analysis

Long-Term Care Software Market - https://www.pharmiweb.com/press-release/2025-12-18/long-term-care-software-market-demand-for-evidence-based-medicine-and-research-updates

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com

Comments

Post a Comment

Popular posts from this blog

Chronic Kidney Disease (CKD) Anemia Market Report 2031: Drivers, Challenges, and Competitive Landscape

-
  Chronic Kidney Disease (CKD) Anemia Market Overview: The global chronic kidney disease (CKD) anemia market is projected to grow at a CAGR of approximately 6% over the next five years. This growth is primarily driven by the rising prevalence of CKD and associated anemia, continuous therapeutic innovations, advancements in diagnostics and personalized medicine, and increasing healthcare expenditure alongside expanding healthcare infrastructure. Download Sample PDF Copy: https://meditechinsights.com/chronic-kidney-disease-anemia-market/request-sample/ CKD-related anemia is a common complication characterized by reduced hemoglobin levels due to impaired kidney function. Healthy kidneys produce erythropoietin, a hormone that stimulates red blood cell production. However, in CKD patients, decreased erythropoietin production, iron deficiency, chronic inflammation, and shortened red blood cell lifespan contribute to anemia. This condition leads to symptoms such as fatigue, breathl...
Read more

Dental 3D Printing Market 2030 | Size, Share. Growth, Analysis and Research Report to Forecast

-
  Dental 3D Printing Market The dental 3D printing market is witnessing robust growth, with an anticipated compound annual growth rate (CAGR) of approximately 20% over the forecast period. This expansion is driven by the rising demand for customized dental solutions, continuous advancements in biocompatible materials, and the increasing integration of digital dentistry across dental practices. Despite its strong growth potential, the market faces challenges such as high initial capital requirements, complex regulatory frameworks, and material constraints that may hinder widespread adoption. Download Sample PDF Copy: https://meditechinsights.com/dental-3d-printing-market/request-sample/ Dental 3D printing is an advanced digital manufacturing technology used to produce dental restorations, prosthetics, and orthodontic models with exceptional precision and accuracy. The technology leverages materials including resins, ceramics, and metal alloys to fabricate customized dental im...
Read more

Biopharmaceuticals Market Size, Share, Growth, Research Report Forecast by 2030

-
  Biopharmaceuticals Market Overview: The global biopharmaceuticals market is projected to grow at a compound annual growth rate (CAGR) of approximately 12% over the next five years. Key factors driving this growth include the rising prevalence of chronic diseases, rapid advancements in biotechnology, an expanding geriatric population, increased adoption of biosimilars, and growing investments in research and development. Download Sample Copy: https://meditechinsights.com/biopharmaceuticals-market/request-sample/ Biopharmaceuticals are therapeutic products developed from biological sources such as living cells or organisms through advanced biotechnological processes. Unlike conventional chemically synthesized drugs, biopharmaceuticals are typically large and complex molecules, including proteins, nucleic acids, or even living cells. Prominent examples include monoclonal antibodies, recombinant proteins, vaccines, and gene and cell therapies. These therapies are designed to t...
Read more